ClinicalTrials.gg
CompletedNCT07767838Updated Aug 17, 2026

Nipple Reinnervation in Two-stage Alloplastic Breast Reconstruction.

An interventional study of Nipple neurotization in Breast Reconstruction, sponsored by Hospital Angeles del Pedregal. Completed at 1 site in Mexico. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Hospital Angeles del Pedregal · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Jan 2021, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

A prospective study was conducted including patients undergoing nipple-sparing mastectomy with neurotization during expander-to-implant exchange between 2021 and 2025.

Read the detailed description

The investigators conducted a prospective study including consecutive patients undergoing nipple-sparing mastectomy (NSM) with nipple neurotization at the time of expander-to-implant exchange between 2021 and 2025.

02

Conditions studied

  • Breast Reconstruction

Keywords

  • Breast reconstruction
03

In context

Lead sponsor

Hospital Angeles del Pedregal is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patients (≥18 years of age).
  • Patients who underwent nipple-sparing mastectomy (NSM) with immediate tissue-expander placement.
  • Patients undergoing nipple neurotization at the time of expander-to-implant exchange.
  • Patients with a clinically viable nipple-areola complex (NAC) at the time of neurotization.
  • Patients who underwent standardized sensory assessment of the breast/NAC preoperatively and at least one postoperative time point.
  • Patients who provided for participation and postoperative sensory assessment.

Exclusion criteria

Exclusion criteria

  • Patients younger than 18 years of age.
  • Male patients.
  • Patients who underwent a mastectomy other than nipple-sparing mastectomy.
  • Patients who underwent nipple neurotization at a time other than the expander-to-implant exchange.
  • Patients unable to undergo standardized sensory testing or unable to reliably report sensory perception.
  • Patients without adequate postoperative follow-up to perform the required sensory assessments.
  • Patients who declined participation or withdrew consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Surgery

    Procedure: Nipple neurotization

Interventions

  • ProcedureNipple neurotization

    Nipple neurotization

06

What researchers measure

Primary outcomes

  1. Sensory evaluation was performed in each zone using the British Medical Research Council (BMRC) scale

    Sensory recovery will be assessed using the British Medical Research Council Sensory Scale, which grades sensory function from S0 to S4. S0 represents complete absence of sensation, while S4 represents normal sensation. The scale includes intermediate grades (S1, S2, S2+, S3, and S3+) reflecting progressive recovery of pain, tactile sensation, and two-point discrimination. The minimum value is S0 and the maximum value is S4; higher scores indicate better sensory recovery.

    Time frame: 1 year

  2. Sensory evaluation was performed in each zone using the Semmes-Weinstein monofilament test.

    Sensory function will be assessed using Semmes-Weinstein monofilament testing with the Baseline Tactile Monofilament Test Kit, consisting of monofilaments calibrated to apply forces of 0.07 g, 0.4 g, 2.0 g, 4.0 g, and 300 g. The lowest force detected by the participant will be recorded as the sensory threshold. A lower detection threshold indicates better sensory function, with 0.07 g representing the best possible result and failure to detect the 300 g monofilament representing the worst possible result.

    Time frame: 1 year

07

Study locations

1 site
  • Hospital Angeles Pedregal
    Mexico City, Mexico City 10700, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2025, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 17, 2026
StartActual
Jan 1, 2021
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07767838
Lead sponsor
Hospital Angeles del Pedregal
Responsible party
Jose Eduardo Telich Tarriba (Plastic Surgeon, Hospital Angeles del Pedregal) — Principal investigator
First posted
Aug 17, 2026
Start date
Jan 1, 2021
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Aug 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion